Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$7.44 -2.2%	$10.86	$5.32 ▼ $17.17	$739.86M	1.26	103,084 shs	29,588 shs
INDV Indivior	$22.84 +2.5%	$16.23	$7.33 ▼ $23.16	N/A	0.74	4.44 million shs	2.57 million shs
KYMR Kymera Therapeutics	$39.87 +5.8%	$44.93	$19.44 ▼ $53.27	$2.45B	2.18	595,396 shs	939,787 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	-1.17%	-8.86%	-18.26%	-33.13%	+760,999,900.00%
INDV Indivior	+1.32%	+5.04%	+44.09%	+99.20%	+76.90%
KYMR Kymera Therapeutics	-7.24%	-13.70%	-15.29%	+21.00%	-9.07%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INDV Indivior	2.0779 of 5 stars	1.6	1.0	0.0	0.0	3.2	1.7	3.1
KYMR Kymera Therapeutics	3.0633 of 5 stars	4.6	3.0	0.0	0.0	1.0	2.5	0.0
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
INDV Indivior	3.17	Buy	$19.60	-14.19% Downside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	48.26% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BGM, INDV, MOR, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	INDV Indivior	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/22/2025	INDV Indivior	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/30/2025	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$25.10M	28.82	N/A	N/A	$7.34 per share	1.01
INDV Indivior	$1.19B	N/A	$1.87 per share	12.24	($2.52) per share	N/A
KYMR Kymera Therapeutics	$47.07M	55.16	N/A	N/A	$12.90 per share	3.09
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
INDV Indivior	$2M	$0.62	36.84	13.36	N/A	6.65%	-86.28%	16.26%	10/23/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-616.03%	-32.86%	-28.19%	10/30/2025 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A

Latest BGM, INDV, MOR, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
7/31/2025	Q2 2025	INDV Indivior	$0.26	$0.51	+$0.25	$0.14	$239.43 million	$302.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.82	1.45
INDV Indivior	N/A	0.90	0.76
KYMR Kymera Therapeutics	N/A	8.49	8.49
MOR MorphoSys	4.98	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
INDV Indivior	60.33%
KYMR Kymera Therapeutics	N/A
MOR MorphoSys	18.38%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
INDV Indivior	N/A
KYMR Kymera Therapeutics	16.01%
MOR MorphoSys	0.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
INDV Indivior	1,051	N/A	N/A	Not Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable

BGM, INDV, MOR, and KYMR Headlines

Recent News About These Companies

MorphoSys takeover delivers phase 3 win for Novartis

August 11 at 9:49 AM | pharmaphorum.comP

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

August 11 at 9:49 AM | biopharmadive.comB

Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer

June 17, 2025 | finance.yahoo.com

Essential Thrombocythemia Market Set for Significant Growth Across 7MM | DelveInsight

March 21, 2025 | theglobeandmail.com

Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts

February 12, 2025 | seekingalpha.com

VIDEO: Triplet therapy improved PFS in relapsed, refractory follicular lymphoma

January 15, 2025 | healio.comH

Novartis closing Morphosys facilities, laying off 330 workers

January 8, 2025 | bioworld.comB

Swiss pharma giant Novartis to close biotech firm Morphosys

December 20, 2024 | swissinfo.chS

Novartis to shut MorphSys sites amid pelabresib delay

December 20, 2024 | thepharmaletter.comT

Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs

December 19, 2024 | biospace.comB

Novartis sheds MorphoSys staff, sites after pelabresib delay

December 19, 2024 | pharmaphorum.comP

Novartis shutters MorphoSys sites, lays off staff

December 19, 2024 | finance.yahoo.com

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

December 19, 2024 | reuters.com

Novartis raises mid-term sales guidance

November 21, 2024 | seekingalpha.com

Novartis: launch of Morphosys drug by could be 2027 or later

November 21, 2024 | reuters.com

Idiopathic Membranous Nephropathy Market Size is estimated to grow with a significant CAGR during the study period (2020-2034).

November 14, 2024 | theglobeandmail.com

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

November 12, 2024 | manilatimes.netM

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale

November 6, 2024 | biopharmadive.comB

Tango stock plunges 28% amid pipeline updates, Q3 earnings report

November 6, 2024 | msn.com

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug

November 1, 2024 | biopharmadive.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BGM, INDV, MOR, and KYMR Company Descriptions

BGM Group NASDAQ:BGM

$7.44 -0.17 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$7.43 -0.01 (-0.13%)

As of 05:48 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Indivior NASDAQ:INDV

$22.84 +0.55 (+2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$22.87 +0.03 (+0.13%)

As of 06:10 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Kymera Therapeutics NASDAQ:KYMR

$39.87 +2.19 (+5.81%)

Closing price 04:00 PM Eastern

Extended Trading

$39.84 -0.03 (-0.09%)

As of 05:48 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 08/11/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time